| ★阿修羅♪ > 不安と不健康10 > 202.html ★阿修羅♪ |
|
| Tweet |
エイズの薬の大手でもあるグラクソ･スミス･クラインはHIVのワクチン開発を目的とするNPO、IAVIと共にワクチン開発に乗り出し、成功した場合は安価に発展途上国に供給することを約束した。研究は感染力のない、チンパンジーの免疫を破壊するウイルスを使って行われる。ワクチンをまずアフリカ向けに安く提供すると言う発表は好意を持って受け入れられているが、グラクソは南アでエイズ薬の特許継続とコピー商品の禁止を求める裁判を展開していることで非難を受けている。
また、グラクソの発展途上国向けに価格を抑えた薬がイギリスに戻っている[Guardian 4月25日]というスキャンダルも起きていた。
http://news.independent.co.uk/business/news/story.jsp?story=648738
GSK looks to develop cheap HIV vaccine
By Stephen Foley
22 June 2005
GlaxoSmithKline, the UK's biggest drug maker, has promised to step up work to find a vaccine against HIV and has promised to sell any product at affordable prices to the developing world.
The company yesterday said it was setting up a joint research team with the not-for-profit International Aids Vaccine Initiative to concentrate work on what it hopes will be a breakthrough approach to the virus.
The pair will collaborate on a treatment derived from a chimpanzee virus which has been engineered to be non-infectious but which could spark the immune systems of humans into responding against HIV.
The agreement was hailed as the first-ever product development collaboration between a major vaccine maker and the IAVI, which has received funding from governments, charities and corporate donors.
It comes as GSK, headed by John-Pierre Garnier, prepares to tell the City about its most exciting new vaccines work, in a research day next Thursday. "The private sector has an immense amount of knowledge, resources and expertise," Jean Stéphenne, the president of GSK Biologicals, the company's vaccines arm said. "Innovative partnerships such as this are essential to tackle the biggest global health challenges."
Although the collaboration will aid GSK's efforts to find a global vaccine, from which it can expect to make large profits in the West, it will initially concentrate its efforts on variants of the disease most prevalent in Africa, where up to 60 per cent of the population may be living with the virus. The treatment is yet to be tested on humans and could take up to a decade to develop.
The IAVI will contribute funding and expertise to the collaboration. Public-private partnerships of this kind are becoming more common as a means of stimulating drug companies to invest in developing world diseases, where traditional research may struggle to make a commercial return.
The agreement was welcomed by the UK government, one of the IAVI's backers. The G8 summit in Scotland next month is likely to decide upon additional measures to encourage vaccines and other drug research work to tackle developing world diseases such as tuberculosis and malaria.
GSK has struggled to shake off its status as bogeyman after it led an industry lawsuit against the South African government in 2001 to try to uphold its patents on Aids drugs there and stop cheap copycats.
▲このページのＴＯＰへ HOME > 不安と不健康10掲示板
題名には必ず「阿修羅さんへ」と記述してください。